Table 3.
Correlation between VTE development and green tea intake as well as other risk factors.
| Predictors | Univariate-HR (95%CI) |
P-value | Multivariate-HR (95%CI) |
P-value |
|---|---|---|---|---|
| No green tea intake (green tea intake as 1.0) | 1.701(1.325–2.077) | 0.001 | 1.758(1.476–2.040) | <0.001 |
| Age (age < 65 years old as 1.0) | 1.205(1.007–1.401) | 0.538 | ||
| BMI (BMI < 35 kg/m2 as 1.0) | 1.218(1.016–1.420) | 0.462 | ||
| Previous VTE (no previous VTE history as 1.0) | 1.669(1.347–1.991) | 0.001 | 1.737(1.305–2.169) | 0.001 |
| Hypercoagulability (no hypercoagulability as 1.0) | 1.931(1.427–2.435) | <0.001 | 1.824(1.336–2.312) | <0.001 |
| Medical comorbidities (no medical comorbidities as 1.0) | 1.552(1.234–1.870) | 0.005 | 1.616(1.317–1.915) | 0.003 |
| Primary site of cancer (cancer of high VTE risk as 1.0) | 1.443(1.135–1.752) | 0.017 | 1.229(1.038–1.421) | 0.134 |
| PS (PS < 2 points as 1.0) | 1.664(1.247–2.081) | 0.001 | 1.603(1.233–1.973) | 0.002 |
| Metastasis (no metastasis as 1.0) | 1.772(1.391–2.153) | 0.001 | 1.785(1.416–2.154) | <0.001 |
| VTE-related anticancer therapies (no VTE-related anticancer therapies as 1.0) | 1.836(1.351–2.321) | <0.001 | 1.935(1.410–2.460) | <0.001 |
| CVC (no CVC as 1.0) | 1.651(1.226–2.076) | 0.004 | 1.702(1.327–2.077) | 0.001 |
| Hospitalization or prolonged immobilization (no hospitalization or prolonged immobilization as 1.0) | 1.508(1.212–1.806) | 0.016 | 1.332(1.114–1.550) | 0.075 |
| Platelet (platelet<350 × 109/L as 1.0) | 1.695(1.248–2.142) | 0.001 | 1.506(1.207–1.805) | 0.002 |
| Hemoglobin (hemoglobin>100 g/L as 1.0) | 1.223(1.008–1.438) | 0.538 | ||
| Use of red cell growth factors (no use of red cell growth factors as 1.0) | 1.447(1.159–1.735) | 0.012 | 1.261(1.042–1.481) | 0.646 |
| Leukocyte (leukocyte<11 × 109/L as 1.0) | 1.315(1.142–1.661) | 0.025 | 1.139(1.025–1.367) | 0.773 |
| D-dimer (D-dimer<1.44 mg/L as 1.0) | 2.058(1.675–2.441) | 0.001 | 1.863(1.453–2.273) | <0.001 |
| Khorana score (Khorana score < 2 as 1.0) | 1.531(1.258–1.804) | 0.010 | 1.645(1.298–2.039) | 0.001 |
| No thromboprophylaxis (thromboprophylaxis as 1.0) | 1.696(1.234–2.158) | 0.001 | 1.712(1.227–2.197) | <0.001 |
VTE, venous thromboembolism; HR, hazard ratio; CI, confidence interval; BMI, body mass index; kg/m2, kilogram/meter2; PS, performance status; CVC, central venous catheterization; L, liter; g/L, gram/liter; mg/L, milligram/liter. Medical comorbidities denote infection, renal disease, pulmonary disease, congestive heart failure, or arterial thromboembolism at the diagnosis of cancer. VTE-related anticancer therapies denote major surgery, chemotherapy, immunotherapy, protein kinase inhibitor, hormonal therapies, and antiangiogenic therapies.